MetaVia announced positive interim data from its Phase 1 clinical trial for DA-1726, a GLP-1 and glucagon receptor dual agonist. After 16 weeks of treatment, the drug demonstrated statistically significant reductions in liver fat, body weight, and HbA1c in adults with obesity. Based on these results, the company plans to advance the drug into a Phase 2 study for liver-related diseases.
Key Details
- Primary Efficacy: The trial showed a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted reduction in body weight. It also achieved a 0.24 percentage-point placebo-adjusted reduction in HbA1c in non-diabetic participants.
- Future Development: MetaVia intends to initiate a 48-week, non-biopsy Phase 2 study of DA-1726 in up to 150 patients with Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), targeted to begin in the second half of 2027.
- Safety & Timeline: The drug was generally well-tolerated, with no study discontinuations due to gastrointestinal adverse events. The company expects to report full data from the Phase 1 trial in the first quarter of 2027.